These five drugs correspond to different generations of inhibitors of the quimeric fusion gene BCR-ABL1, and are all used to treat of Philadelphia chromosome-positive Chronic Myelogenous Leukemia [22]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.